$35.53
0.41[1.17%]
Last update: 9:30AM Get Real Time Here
Tandem Diabetes Care
(NASDAQ:TNDM)Tandem Diabetes Care Stock (NASDAQ:TNDM), Analyst Ratings, Price Targets, Predictions
Tandem Diabetes Care Inc has a consensus price target of $44.71, established from looking at the 54 latest analyst ratings. The last 3 analyst ratings were released from Leerink Partners, Stifel, and Citigroup on April 25, 2024, April 23, 2024, and April 3, 2024. With an average price target of $41 between Leerink Partners, Stifel, and Citigroup, there's an implied 15.40% upside for Tandem Diabetes Care Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Stifel
Citigroup
Stifel
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Tandem Diabetes Care
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/25/2024 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | 26.65% | Leerink Partners | Mike Kratky | $34 → $45 | Upgrade | Market Perform → Outperform | Get Alert |
| 04/23/2024 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | 12.58% | Stifel | Mathew Blackman | $37 → $40 | Maintains | Buy | Get Alert |
| 04/03/2024 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | 6.95% | Citigroup | Joanne Wuensch | $31 → $38 | Maintains | Neutral | Get Alert |
| 03/26/2024 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | 4.14% | Stifel | Mathew Blackman | — | Upgrade | Hold → Buy | Get Alert |
| 03/15/2024 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -12.75% | Citigroup | Joanne Wuensch | $25 → $31 | Maintains | Neutral | Get Alert |
| 02/05/2024 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -32.45% | Stifel | Rick Wise | $17 → $24 | Maintains | Hold | Get Alert |
| 11/02/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -29.64% | Piper Sandler | Matt O'Brien | $40 → $25 | Maintains | Overweight | Get Alert |
| 10/16/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -40.9% | Leerink Partners | Mike Kratky | → $21 | Initiates | → Market Perform | Get Alert |
| 10/02/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -35.27% | Citigroup | Joanne Wuensch | $31 → $23 | Maintains | Neutral | Get Alert |
| 10/02/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | 26.65% | Jefferies | Matthew Taylor | $47 → $45 | Maintains | Buy | Get Alert |
| 08/21/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -12.75% | Citigroup | Joanne Wuensch | $33 → $31 | Maintains | Neutral | Get Alert |
| 08/21/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -9.94% | Baird | Jeff Johnson | $33 → $32 | Maintains | Neutral | Get Alert |
| 08/07/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | 74.5% | Barclays | Matt Miksic | $71 → $62 | Maintains | Overweight | Get Alert |
| 08/04/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -4.31% | TD Cowen | Joshua Jennings | $52 → $34 | Maintains | Outperform | Get Alert |
| 08/04/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -15.56% | Wells Fargo | Larry Biegelsen | $40 → $30 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -7.12% | Baird | Jeff Johnson | $38 → $33 | Maintains | Neutral | Get Alert |
| 08/04/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | -7.12% | Citigroup | Joanne Wuensch | $45 → $33 | Downgrade | Buy → Neutral | Get Alert |
| 06/13/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | 40.73% | Craig-Hallum | Alexander Nowak | $74 → $50 | Maintains | Buy | Get Alert |
| 06/05/2023 | TNDM | Buy Now | Tandem Diabetes Care | $35.53 | 26.65% | Citigroup | Joanne Wuensch | $55 → $45 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Tandem Diabetes Care (TNDM)?
The latest price target for Tandem Diabetes Care (NASDAQ: TNDM) was reported by Leerink Partners on April 25, 2024. The analyst firm set a price target for $45.00 expecting TNDM to rise to within 12 months (a possible 26.65% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tandem Diabetes Care (TNDM)?
The latest analyst rating for Tandem Diabetes Care (NASDAQ: TNDM) was provided by Leerink Partners, and Tandem Diabetes Care upgraded their outperform rating.
When was the last upgrade for Tandem Diabetes Care (TNDM)?
The last upgrade for Tandem Diabetes Care Inc happened on April 25, 2024 when Leerink Partners raised their price target to $45. Leerink Partners previously had a market perform for Tandem Diabetes Care Inc.
When was the last downgrade for Tandem Diabetes Care (TNDM)?
The last downgrade for Tandem Diabetes Care Inc happened on August 4, 2023 when Citigroup changed their price target from $45 to $33 for Tandem Diabetes Care Inc.
When is the next analyst rating going to be posted or updated for Tandem Diabetes Care (TNDM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tandem Diabetes Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tandem Diabetes Care was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
Is the Analyst Rating Tandem Diabetes Care (TNDM) correct?
While ratings are subjective and will change, the latest Tandem Diabetes Care (TNDM) rating was a upgraded with a price target of $34.00 to $45.00. The current price Tandem Diabetes Care (TNDM) is trading at is $35.53, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.